BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 69,744 shares of the company’s stock in a transaction on Monday, November 21st. The stock was sold at an average price of $87.56, for a total value of $6,106,784.64. The sale was disclosed in a filing with the SEC, which is available at this link.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Tuesday, November 22nd, Jean Jacques Bienaime sold 69,743 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $85.69, for a total value of $5,976,277.67.
  • On Monday, November 7th, Jean Jacques Bienaime sold 70,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $82.52, for a total value of $5,776,400.00.
  • On Tuesday, November 8th, Jean Jacques Bienaime sold 140,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $82.67, for a total value of $11,573,800.00.
  • On Friday, October 28th, Jean Jacques Bienaime sold 120,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $81.30, for a total value of $9,756,000.00.
  • On Monday, October 17th, Jean Jacques Bienaime sold 41,666 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $84.39, for a total value of $3,516,193.74.
  • On Friday, October 14th, Jean Jacques Bienaime sold 64,125 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $86.96, for a total value of $5,576,310.00.
  • On Thursday, September 29th, Jean Jacques Bienaime sold 53,125 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $93.65, for a total value of $4,975,156.25.
  • On Friday, September 16th, Jean Jacques Bienaime sold 137,368 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $95.34, for a total value of $13,096,665.12.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 88.10 on Friday. The company’s 50-day moving average price is $86.66 and its 200 day moving average price is $89.49. BioMarin Pharmaceutical Inc. has a 52-week low of $62.12 and a 52-week high of $107.56. The company’s market capitalization is $15.15 billion.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, October 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.13. BioMarin Pharmaceutical had a negative return on equity of 8.54% and a negative net margin of 46.22%. The business earned $279.90 million during the quarter, compared to analyst estimates of $289.70 million. During the same quarter in the previous year, the company posted ($0.60) earnings per share. BioMarin Pharmaceutical’s revenue for the quarter was up 34.0% on a year-over-year basis. On average, equities analysts expect that BioMarin Pharmaceutical Inc. will post ($3.73) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

A number of research analysts have issued reports on BMRN shares. Vetr upgraded BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating and set a $111.64 price objective for the company in a research note on Wednesday, August 24th. Wedbush restated a “neutral” rating and issued a $108.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, July 28th. Jefferies Group restated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, August 17th. Zacks Investment Research upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $111.00 price objective for the company in a research note on Tuesday, August 9th. Finally, Cowen and Company set a $150.00 price objective on BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, September 8th. Five equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $115.24.

A number of hedge funds have recently added to or reduced their stakes in the stock. Cornerstone Advisors Inc. raised its stake in BioMarin Pharmaceutical by 22.0% in the third quarter. Cornerstone Advisors Inc. now owns 1,159 shares of the company’s stock valued at $107,000 after buying an additional 209 shares in the last quarter. Rockefeller Financial Services Inc. acquired a new position in BioMarin Pharmaceutical during the second quarter worth $111,000. Independent Portfolio Consultants Inc. acquired a new position in BioMarin Pharmaceutical during the third quarter worth $121,000. Toronto Dominion Bank raised its position in BioMarin Pharmaceutical by 57.8% in the third quarter. Toronto Dominion Bank now owns 1,401 shares of the company’s stock worth $130,000 after buying an additional 513 shares during the period. Finally, Meeder Asset Management Inc. acquired a new position in BioMarin Pharmaceutical during the second quarter worth $140,000. 93.68% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Jean Jacques Bienaime Sells 69,744 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2016/11/25/jean-jacques-bienaime-sells-69744-shares-of-biomarin-pharmaceutical-inc-bmrn-stock.html.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.